P/E ratio for Aldeyra Therapeutics (ALDX)
P/E ratio as of April 2024 (TTM): -4.42
According to Aldeyra Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.41573. At the end of 2022 the company had a P/E ratio of -6.57.
P/E ratio history for Aldeyra Therapeutics from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -6.57 | 75.64% |
| 2021 | -3.74 | -38.97% |
| 2020 | -6.13 | 135.09% |
| 2019 | -2.61 | -43.5% |
| 2018 | -4.61 | -5.07% |
| 2017 | -4.86 | 51.62% |
| 2016 | -3.20 | -33.85% |
| 2015 | -4.84 | 40.35% |
| 2014 | -3.45 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | 23.6 | -635.37% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.